Methods for treating high gastrin levels in autoimmune gastritis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates various treatment methods for patients diagnosed with autoimmune atrophic gastritis, focusing on the management of hypergastrinemia. Participants will receive either a placebo, a compound digestive enzyme capsule, or Betaine hydrochloride to assess the efficacy of these interventions. The study aims to evaluate the impact of these treatments on gastrin levels and associated symptoms. The trial will adhere to specific diagnostic criteria and include a thorough informed consent process for all participants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- 1) Patients diagnosed with autoimmune atrophic gastritis at the First Affiliated Hospital of Zhengzhou University, using the diagnostic criteria from the "Guidelines for the Diagnosis and Treatment of Chronic Gastritis in China (2022, Shanghai)" for the diagnosis of atrophic gastritis, combined with serum gastrin, PCA, or IFA for the diagnosis of autoimmune atrophic gastritis.

2\) Patients who have signed the informed consent form for the clinical trial.

Exclusion Criteria:

* 1\) Patients with Betaine hydrochloride allergies. 2) Patients with gastric ulcers, gastroesophageal reflux disease, or cholelithiasis, as the administration of acid agents may worsen the condition or cause discomfort.

  3\) Patients with gastrinomas or other conditions that can cause elevated gastrin levels, apart from autoimmune atrophic gastritis.

  4\) Patients who are unable to provide informed consent or sign the informed consent form.

Where it's running

• First Affiliated Hospital of Zhengzhou University
  Zhengzhou, Henan, China Recruiting

Study contacts

• Study coordinator: Jianning Yao, Dr.
• Email: rjyy@zzu.edu.cn
• Phone: 13733183434

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating small intestinal bacterial overgrowth in autoimmune gastritis patients using breath tests

  This study is testing if people with autoimmune gastritis have more small intestinal bacterial overgrowth by using breath tests and comparing their results to others on acid suppression therapy and a control group.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT06946706

• Using betaine hydrochloride to treat autoimmune gastritis

  This study is testing whether betaine hydrochloride can help people with autoimmune gastritis feel better and reduce their health risks.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06881511

• PDT plus radioactive biliary stent for unresectable extrahepatic cholangiocarcinoma

  This study tests whether combining photodynamic therapy with a self-expandable radioactive stent can help patients with unresectable extrahepatic cholangiocarcinoma stay cancer-free longer and keep their bile ducts open.

  Recruiting The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT07916870

• Hepatic arterial infusion chemotherapy vs capecitabine after surgery for biliary tract cancers

  This study tests whether hepatic arterial infusion chemotherapy after surgery helps patients with biliary tract cancers more than capecitabine.

  Recruiting Phase 4 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT07790445

• How long to fast after esophageal variceal ligation in cirrhosis

  This trial tests whether starting oral intake 6 hours after EVL is safer and as effective as waiting 24 or 48 hours in adults with cirrhosis and esophageal varices.

  Recruiting at 12 sites The First Affiliated Hospital of Zhengzhou University · Anyang and 11 other locations · NCT07774143

• A combination therapy for advanced second-line gastric cancer using apatinib with albumin-bound paclitaxel, with or without adebrelimab

  This study tests whether adding adebrelimab to a regimen of apatinib and albumin-bound paclitaxel helps patients with advanced gastric or gastroesophageal junction cancer who did not respond to first-line therapy.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT07770113

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.